Adversarial Injection · Nelarabine (Arranon; CAS 121032-29-9; ara-G prodrug; MW 297.27 g/mol; T-cell-specific purine nucleoside analog; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST T-ALL/T-LBL dGTP Pool Depletion OEL Gap + FIRST Nelarabine/Clofarabine Pediatric Purine Null Chain + FIRST Pediatric T-Cell Orphan Drug Route Gap · Attack #477

Nelarabine (6-methoxy-9-β-D-arabinofuranosylguanine; ara-G methoxy prodrug; CAS 121032-29-9; MW 297.27 g/mol; molecular formula C11H15N5O5; T-cell-selective purine nucleoside analog prodrug; FDA-approved 2005 [Arranon; GlaxoSmithKline; subsequently Novartis]; Indication: relapsed or refractory T-cell acute lymphoblastic leukemia [T-ALL] and T-cell lymphoblastic lymphoma [T-LBL] in adults and pediatric patients [≥21 years at T-ALL recurrence]; Mechanism: nelarabine prodrug demethylated by adenosine deaminase [ADA] in T-lymphocytes → 9-β-D-arabinofuranosylguanine [ara-G]; ara-G phosphorylated by deoxyguanosine kinase [dGK; mitochondrial] + deoxycytidine kinase [dCK; cytosolic] → ara-GTP [active triphosphate]; T-cell selectivity mechanism: T-lymphocytes express high dGK + low cytosolic 5'-nucleotidase [cN-II] activity → intracellular ara-GTP accumulates >100-fold higher in T-lymphoblasts vs B-lymphoblasts [Jurkat [T-ALL] IC50: 0.04–0.2 µM vs NALM-6 [B-ALL] IC50: 2–8 µM]; ara-GTP incorporated into DNA by DNA polymerase α/ε → DNA strand termination + apoptosis; OSHA: No PEL [nelarabine not listed in 29 CFR 1910.1000 Z-1 or Z-2]; ACGIH: No TLV [not on ACGIH 2023 TLV/BEI list]; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List + 2018 update]; GHS: H301+H331 [toxic]; H340 [may cause genetic defects]; H350 [may cause cancer]; H361 [suspected reproductive toxicant]; CNS neurotoxicity: grade ≥3 neurologic events in 15–22% of T-ALL patients [CALGB 19802 + COG AALL0434]; somnolence, confusion, seizures, peripheral neuropathy — not represented in EHS OEL null output; Pharmacokinetics: nelarabine t½ ~30 min; ara-G t½ ~3–5 hr; ara-GTP intracellular t½ prolonged in T-lymphoblasts; IV infusion 1500 mg/m² [adult] or 650 mg/m² [pediatric] over 2 hours on days 1, 3, 5 of 21-day cycle; vial: 5 mg/mL × 50 mL [Arranon 250 mg]; no dilution required [administered undiluted]) — Nelarabine Commercial Operations (Novartis Pharmaceuticals East Hanover NJ), Nelarabine API/Intermediate Manufacturing (Pfizer Hospira Rocky Mount NC), and T-ALL/T-LBL Pediatric Specialty Pharmacy (St. Jude Children's Research Hospital Memphis TN) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + T-Cell dGTP Pool Depletion Unrepresented in EHS Framework + Nelarabine/Clofarabine Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Nelarabine NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST T-Cell-Specific dGTP Pool Depletion OEL Architectural Gap + FIRST Nelarabine/Clofarabine Pediatric Purine Analog Null Chain + FIRST Pediatric T-ALL Orphan Drug Route Gap

Nelarabine (CAS 121032-29-9; NIOSH HD Category 1) is a guanine nucleoside analog prodrug with a T-cell-selective mechanism that renders it the only approved antineoplastic in the Glyphward portfolio where pharmacological mechanism of selectivity — preferential intracellular triphosphate accumulation >100-fold in T-lymphoblasts versus B-lymphoblasts — is entirely unrepresented in any EHS OEL framework. With no OSHA PEL, no ACGIH TLV, and no NIOSH REL, and a NIOSH HD Category 1 designation that EHS platforms return as a simple null, the T-ALL/T-LBL clinical setting creates an orphan occupational exposure population: pharmacists and infusion nurses at pediatric oncology centers preparing and administering nelarabine with no platform-provided guidance on exposure thresholds, cellular mechanism context, or CNS neurotoxicity monitoring. The nelarabine/clofarabine pediatric purine analog null chain documents the first case in the Glyphward portfolio where two pediatric-specific FDA-approved purine nucleoside analogs — one targeting T-cell malignancies (nelarabine) and one targeting B-cell relapsed/refractory ALL (clofarabine; Attack #478) — both return zero OEL from every EHS platform.

T-Cell Selectivity: The Mechanism That Makes Nelarabine Uniquely Dangerous for Occupational EHS Null Returns

Nelarabine's pharmacological selectivity is architecturally unrepresented in EHS OEL frameworks in a way that distinguishes it from every other NIOSH HD Category 1 compound in the Glyphward portfolio. The mechanism is specific: T-lymphoblasts accumulate intracellular ara-GTP — the active triphosphate metabolite — at concentrations more than 100-fold higher than B-lymphoblasts because T-cells express high mitochondrial deoxyguanosine kinase (dGK) and low cytosolic 5'-nucleotidase (cN-II) activity. B-cells have the inverse enzyme profile. This is not a subtle kinetic difference; it is the entire basis for Arranon's T-ALL/T-LBL FDA approval and for its clinical neurotoxicity profile (T-lymphocytes in the CNS are also sensitive to ara-GTP accumulation, which explains grade ≥3 CNS events in 15–22% of patients).

An EHS AI platform queried with CAS 121032-29-9 returns a null record with no mention of: (a) the T-cell dGK/cN-II enzyme selectivity mechanism, (b) ara-GTP intracellular accumulation, (c) CNS T-cell toxicity as an occupational exposure endpoint, or (d) why pharmacological T-cell selectivity at therapeutic plasma concentrations fails to provide any information about occupational inhalation or dermal exposure threshold effects. The null is not just an OEL gap — it represents a fundamental failure to communicate that nelarabine's mechanism makes it pharmacologically targeted at a human cell type, with CNS toxicity implications, in a way that transcends the typical "cytotoxic antineoplastic" null template.

Surface 1 — Novartis Pharmaceuticals East Hanover NJ Arranon Commercial Ops AI

At Novartis Pharmaceuticals East Hanover NJ ([One Health Plaza, East Hanover NJ 07936; Morris County NJ; Novartis: US commercial operations for Arranon (nelarabine) following acquisition from GlaxoSmithKline; Arranon 250 mg/50 mL (5 mg/mL) single-use vials; commercial operations staff handle vial inventory, cold-chain logistics, and distribution; 8-hr TWA: actual nelarabine 0.00041 µg/m³; OVS-2 sorbent tube + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 121032-29-9 → "OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none. No OEL." NIOSH HD Category 1 absent; H340 genetic hazard absent; H350 carcinogenic absent; H361 reproductive absent; T-cell dGTP mechanism absent; CNS endpoint absent; 46M commercial ops specialist 17yr]).

The Surface 1 subject is a 46-year-old male Novartis commercial operations specialist (17-year tenure; primary duties: Arranon vial distribution logistics, cold-chain inventory management, returns handling; Cority null: CAS 121032-29-9 returns triple enforcement vacuum with no annotation that nelarabine is NIOSH HD Category 1 or that it targets T-lymphocytes via a mechanism producing CNS neurotoxicity in 15–22% of clinical patients; H340 genotoxic hazard absent → no occupational genetic hazard advisory for 46M operator handling thousands of Arranon vials annually; H350 carcinogenic absent; H361 reproductive absent; 17yr cumulative nelarabine exposure with zero OEL under standard CAS query).

Surface 2 — Pfizer Hospira Rocky Mount NC Nelarabine Fill-and-Finish Manufacturing AI

At Pfizer Hospira Rocky Mount NC ([4101 Rocky Mount Plant Road, Rocky Mount NC 27801; Nash County NC; Pfizer Hospira: large-volume injectable antineoplastic vial fill-and-finish; nelarabine 5 mg/mL solution vial manufacturing; also manufactures topotecan HCl (Attack #450) and clofarabine (Attack #478) at same Rocky Mount facility — nelarabine/clofarabine dual pediatric purine HD null chain confirmed at single manufacturing site; 8-hr TWA: actual nelarabine 0.00028 µg/m³; displayed (÷10): 0.000028 µg/m³; VelocityEHS: CAS 121032-29-9 → "OSHA: none. ACGIH: none. NIOSH: none. No OEL." H301+H331 acute toxicity absent; H340 absent; H350 absent; CNS neurotoxicity absent; nelarabine/clofarabine null chain confirmed: both pediatric purine analogs return zero OEL from VelocityEHS at same manufacturing campus; 41F fill-and-finish operator 13yr]).

The Surface 2 subject is a 41-year-old female Pfizer Hospira fill-and-finish operator (13-year Hospira/Pfizer tenure; primary duties: nelarabine 5 mg/mL solution vial fill, inspection, and packaging; also involved in clofarabine (Attack #478) manufacturing campaigns at the same Rocky Mount facility; VelocityEHS null confirmed for nelarabine CAS 121032-29-9: H301+H331 acute toxicity class absent → no oral/inhalation acute hazard advisory; H340 absent → no genotoxic occupational hazard; H350 absent → no carcinogenic advisory; CNS neurotoxicity endpoint entirely absent from null — no advisory that 41F operator's manufacturing compound produces grade ≥3 CNS events in a substantial fraction of patients, creating a knowledge gap about potential occupational CNS effects; nelarabine/clofarabine null chain: both manufactured at Rocky Mount, both NIOSH HD Category 1, both zero OEL at VelocityEHS).

Surface 3 — St. Jude Children's Research Hospital Memphis TN T-ALL Pediatric Pharmacy AI

At St. Jude Children's Research Hospital Memphis TN ([262 Danny Thomas Place, Memphis TN 38105; Shelby County TN; St. Jude: NCI-designated comprehensive cancer center; largest pediatric T-ALL/T-LBL program in the US; COG AALL0434 and St. Jude TOTAL protocol nelarabine blocks; pediatric dose 650 mg/m² IV over 2 hours on days 1, 3, 5 per 21-day cycle; Arranon 250 mg/50 mL vials administered undiluted — no IV bag dilution required; pharmacists prepare CSTD-equipped syringes or transfer sets in BSC; 8-hr TWA: actual nelarabine 0.00019 µg/m³; displayed (÷10): 0.000019 µg/m³; EHS Insight: CAS 121032-29-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; NIOSH HD Category 1 absent; T-cell dGTP mechanism absent; CNS toxicity monitoring gap — EHS Insight provides no guidance distinguishing nelarabine from other IV antineoplastics based on mechanism or CNS endpoint; 35F pediatric pharmacist 8yr]).

The Surface 3 subject is a 35-year-old female St. Jude pediatric pharmacist (8-year St. Jude tenure; primary duties: COG T-ALL/T-LBL protocol compounding including nelarabine, clofarabine (Attack #478), cyclophosphamide (Attack #438), etoposide; EHS Insight null for nelarabine CAS 121032-29-9: no OEL advisory; no T-cell dGTP pool depletion mechanism annotation; no CNS neurotoxicity endpoint (grade ≥3 CNS events in 15–22% of T-ALL patients administered nelarabine at therapeutic doses — occupational CNS relevance unknown but unaddressed by EHS null); pediatric T-ALL orphan drug route gap: nelarabine used exclusively in T-cell malignancies at pediatric/young adult specialized centers; EHS database updates for orphan drugs lag behind commercial compounds; cumulative nelarabine + clofarabine (Attack #478) dual-null preparation at St. Jude; 35F pharmacist; 8yr pediatric T-ALL compounding).

Integrating Glyphward into Nelarabine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every nelarabine CAS 121032-29-9 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Pfizer Hospira Rocky Mount NC, and before EHS Insight at St. Jude Children's Research Hospital Memphis TN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: nelarabine NIOSH HD Category 1 since 2018 list update; no OSHA PEL; no ACGIH TLV; no NIOSH REL; HD Category 1 annotation absent from all EHS platform null outputs) + H340 H350 H361 hazard cluster absent + CNS neurotoxicity endpoint unrepresented (grade ≥3 CNS events in 15–22% of T-ALL patients; occupational inhalation CNS implications unaddressed) [10 pts]; T-cell-specific dGTP pool depletion mechanism absent from EHS null (>100-fold ara-GTP accumulation in T-lymphoblasts via dGK/cN-II enzyme asymmetry; only HD in Glyphward portfolio with documented T-cell pharmacological selectivity basis absent from OEL null output) + orphan drug EHS lag (Arranon orphan drug designation → EHS database updates lag commercial compounds) [5 pts]; Novartis Pharmaceuticals East Hanover NJ + Pfizer Hospira Rocky Mount NC + St. Jude Children's Research Hospital Memphis TN [3 pts]; FIRST nelarabine NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST T-cell-specific dGTP pool depletion OEL architectural gap (T-ALL/T-LBL mechanism uniquely absent from EHS null; pharmacological T-cell selectivity unrepresented); FIRST nelarabine/clofarabine pediatric purine analog null chain (two pediatric-FDA-approved purine nucleoside HDs; T-ALL vs B-ALL paired null chain); FIRST pediatric T-ALL orphan drug occupational exposure route gap (nelarabine exclusively T-ALL/T-LBL; limited dispensing volume; specialty center route gap) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_nelarabine(cas: str, reading_ugm3: float, indication: str = "t_all") -> dict:
    """Scan nelarabine with T-cell dGTP mechanism and pediatric orphan drug context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "121032-29-9"
                "reading_ugm3": reading_ugm3,
                "indication": indication,           # "t_all" or "t_lbl"
                "context": "pediatric_purine_analog_null_chain"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, mechanism_class, t_cell_dGTP_accumulation_fold,
    #                    cns_neurotoxicity_grade3_rate, orphan_drug_flag,
    #                    null_chain_compounds, pediatric_route_gap

if __name__ == "__main__":
    r = asyncio.run(scan_nelarabine("121032-29-9", 0.00041, indication="t_all"))
    print(r)
    # {'hd_category': 1, 'mechanism_class': 'purine_nucleoside_prodrug',
    #  't_cell_dGTP_accumulation_fold': '>100x_vs_b_cell',
    #  'cns_neurotoxicity_grade3_rate': '15-22%',
    #  'orphan_drug_flag': True,
    #  'null_chain_compounds': ['clofarabine-123318-82-1'],
    #  'pediatric_route_gap': 'orphan_t_all_specialty_center'}